Sonoma Pharmaceuticals Secures Extensive U.K. Regulatory Clearances of Key Wound Care and Dermatology Products by the Medicines & Healthcare Products Regulatory Agency (MHRA)
Sonoma Pharmaceuticals (NASDAQ:SNOA) has achieved significant regulatory milestones in the United Kingdom, securing MHRA registration for its manufacturing facility and five key products. The approved products include their Microcyn technology-based hypochlorous acid (HOCl) solutions for wound irrigation, scar management, wound hydrogel, and skin exfoliant.
The company, which develops patented Microcyn® technology-based stabilized HOCl products for various applications including wound care, eye, oral, nasal care, dermatological conditions, podiatry, and animal health care, views the UK market as a significant opportunity for expansion, particularly in wound care and dermatology segments.
Sonoma Pharmaceuticals (NASDAQ:SNOA) ha raggiunto importanti traguardi normativi nel Regno Unito, ottenendo la registrazione MHRA per il suo stabilimento di produzione e cinque prodotti chiave. I prodotti approvati includono le loro soluzioni a base di tecnologia Microcyn a base di acido ipocloroso (HOCl) per l'irrigazione delle ferite, la gestione delle cicatrici, il gel idrogel per ferite e l'esfoliante per la pelle.
L'azienda, che sviluppa prodotti stabilizzati a base di HOCl con tecnologia Microcyn® brevettata per varie applicazioni, tra cui la cura delle ferite, la cura degli occhi, orale, nasale, condizioni dermatologiche, podologia e cura della salute animale, considera il mercato britannico come un'importante opportunità di espansione, in particolare nei segmenti della cura delle ferite e della dermatologia.
Sonoma Pharmaceuticals (NASDAQ:SNOA) ha logrado hitos regulatorios significativos en el Reino Unido, asegurando la registro MHRA para su instalación de fabricación y cinco productos clave. Los productos aprobados incluyen sus soluciones de ácido hipocloroso (HOCl) basadas en tecnología Microcyn para la irrigación de heridas, el manejo de cicatrices, gel hidrogel para heridas y exfoliante para la piel.
La empresa, que desarrolla productos estabilizados de HOCl basados en la tecnología Microcyn® patentada para diversas aplicaciones, incluyendo el cuidado de heridas, ocular, oral, nasal, condiciones dermatológicas, podología y cuidado de la salud animal, ve el mercado del Reino Unido como una oportunidad significativa para la expansión, particularmente en los segmentos de cuidado de heridas y dermatología.
소노마 제약 (NASDAQ:SNOA)는 영국에서 중요한 규제 이정표를 달성하여 제조 시설과 5개의 주요 제품에 대한 MHRA 등록을 확보했습니다. 승인된 제품에는 마이크로신 기술 기반의 차아염소산(HOCl) 용액이 포함되어 있으며, 이는 상처 세척, 흉터 관리, 상처 하이드로젤 및 피부 각질 제거제에 사용됩니다.
이 회사는 상처 치료, 눈, 구강, 비강 치료, 피부 질환, 족부 및 동물 건강 관리 등 다양한 용도로 마이크로신® 기술 기반의 안정화된 HOCl 제품을 개발하며, 영국 시장을 특히 상처 치료 및 피부과 부문에서 확장을 위한 중요한 기회로 보고 있습니다.
Sonoma Pharmaceuticals (NASDAQ:SNOA) a atteint des jalons réglementaires significatifs au Royaume-Uni, obtenant l'enregistrement MHRA pour son installation de fabrication et cinq produits clés. Les produits approuvés comprennent leurs solutions à base d'acide hypochloreux (HOCl) basées sur la technologie Microcyn pour l'irrigation des plaies, la gestion des cicatrices, le gel hydrogel pour plaies et l'exfoliant pour la peau.
L'entreprise, qui développe des produits stabilisés à base de HOCl utilisant la technologie Microcyn® brevetée pour diverses applications, y compris les soins des plaies, oculaires, oraux, nasaux, les conditions dermatologiques, la podologie et les soins de santé animale, considère le marché britannique comme une opportunité significative d'expansion, en particulier dans les segments des soins des plaies et de la dermatologie.
Sonoma Pharmaceuticals (NASDAQ:SNOA) hat im Vereinigten Königreich bedeutende regulatorische Meilensteine erreicht und die MHRA-Zulassung für seine Produktionsstätte sowie fünf wichtige Produkte erhalten. Zu den genehmigten Produkten gehören ihre auf Microcyn-Technologie basierenden Lösungen mit hypochloriger Säure (HOCl) zur Wundspülung, Narbenbehandlung, Wundhydrogel und Hautpeeling.
Das Unternehmen, das patentierte auf Microcyn® basierende stabilisierte HOCl-Produkte für verschiedene Anwendungen entwickelt, darunter Wundversorgung, Augen-, Mund-, Nasenpflege, dermatologische Erkrankungen, Podologie und tiermedizinische Versorgung, betrachtet den britischen Markt als eine bedeutende Expansionsmöglichkeit, insbesondere in den Bereichen Wundversorgung und Dermatologie.
- Secured MHRA registration for manufacturing facility and five products in UK
- Entry into significant new market (United Kingdom)
- Expansion of geographical footprint for wound care and dermatology products
- None.
BOULDER, CO / ACCESS Newswire / March 10, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced the registration of its manufacturing facility and five of its products with the Medicines & Healthcare products Regulatory Agency (MHRA) in the United Kingdom. The newly registered products include Sonoma's hypochlorous acid-based wound irrigation solution, scar management products, wound hydrogel, and skin exfoliant.
"Thanks to the diligent efforts of our regulatory team in securing these new registrations with the MHRA, we are now able to bring our safe and effective Microcyn-based products to the United Kingdom," said Amy Trombly, CEO of Sonoma. "The U.K. represents a significant new market for Sonoma, for both our wound care and dermatology products, and we are excited for the opportunities for growth that this new registration provides."
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact busdev@sonomapharma.com.
Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "develop," "anticipate," "expect" and "opportunities," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals™ and Microcyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
ir@sonomapharma.com
Website: www.sonomapharma.com
Follow us on LinkedIn: https://www.linkedin.com/company/sonoma-pharmaceuticals
Follow us on Instagram: https://www.instagram.com/sonomapharma_us/
Follow us on Facebook: https://www.facebook.com/sonomapharma/
SOURCE: Sonoma Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire
FAQ
What products did Sonoma Pharmaceuticals (SNOA) get approved by MHRA in March 2025?
What is the significance of MHRA registration for Sonoma Pharmaceuticals (SNOA)?
What technology does SNOA use in their newly approved UK products?
What markets will SNOA target with their MHRA-approved products?
